A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

Yongchang Zhang

Status: Enrolling

Conditions: Non Small Cell Lung Cancer

Treatments: Drug: immunity therapy

Study type: Observational

Funder types: Other

Identifiers

NCT04777175

IRMLC

Details and patient eligibility

About

In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.

Enrollment: 186 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1.Diagnosed as advanced non-small cell lung cancer
• 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation

Exclusion criteria

• The patient is diagnosed with small cell lung cancer

Trial design

186 participants in 6 patient groups

KRAS mutation

Description:

patients carry with KRAS mutation

Treatment:

Drug: immunity therapy

ALK fusion

Description:

patients carry with ALK fusion

Treatment:

Drug: immunity therapy

ERBB2 mutation

Description:

patients carry with ERBB2 mutation

Treatment:

Drug: immunity therapy

MET skipping/amplication

Description:

patients carry with MET skipping/amplication

Treatment:

Drug: immunity therapy

RET fusion

Description:

patients carry with RET fusion

Treatment:

Drug: immunity therapy

BRAF mutation

Description:

patients carry with BRAF mutation

Treatment:

Drug: immunity therapy